Immatics Announces Full Year 2020 Financial Results and Corporate Update
- Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients
- Enrollment across clinical ACTengine® IMA200 trial series continues to scale up
- Cash and cash equivalents as well as other financial assets of $285 million1 (€232 million) as of December 31, 2020 provide cash reach into 2023
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2020.